The cost-effectiveness of using hepatitis A/B combined vaccine versus hepatitis B vaccine alone for high-risk heterosexuals.

Previous studies estimated that vaccinating high-risk heterosexuals (HRH) with combination hepatitis A/B vaccine was a cost-effective alternative to vaccinating HRH against hepatitis B alone. Since then, the incidence of hepatitis A has declined dramatically in the United States. We re-estimate the cost-effectiveness of this policy accounting for modern declines in incidence. According to our estimates, vaccinating with combination vaccine resulted in a cost of $120,000 per quality adjusted life year gained (2.79 times the 2005 United States Gross Domestic Product per capita), a ratio that is less favorable than those for most other vaccination strategies.
AuthorsDavid B Rein, Cindy M Weinbaum
JournalVaccine (Vaccine) Vol. 26 Issue 42 Pg. 5331-3 (Oct 3 2008) ISSN: 0264-410X [Print] Netherlands
PMID18706957 (Publication Type: Journal Article)
Chemical References
  • Hepatitis A Vaccines
  • Hepatitis B Vaccines
  • Vaccines, Combined
  • Adolescent
  • Adult
  • Cost-Benefit Analysis
  • Hepatitis A (epidemiology, prevention & control)
  • Hepatitis A Vaccines (economics)
  • Hepatitis B (epidemiology, prevention & control)
  • Hepatitis B Vaccines (economics)
  • Heterosexuality
  • Humans
  • Immunization Programs (economics)
  • Incidence
  • Quality-Adjusted Life Years
  • Risk Factors
  • United States (epidemiology)
  • Vaccines, Combined

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: